Intelligence · Patents
Patents expiring in 2032
Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.
- Patents
- 1,123
Quick answer
1,123 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8093214
Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
granted -
US 8092809
Pseudomonas exotoxin A-like chimeric immunogens
granted -
US 8092802
High affinity human antibodies to human IL-4 receptor
granted -
US 8093286
Methods for treatment with bucindolol based on genetic targeting
granted -
US 8093274
Inhibitors of protein prenyltransferases
granted -
US 8093267
Methods of treating rheumatoid arthritis
granted -
US 8093291
Methods of using and compositions comprising tryptophan hydroxylase inhibitors
granted -
US 8092796
Monoclonal antibodies against ANGPTL4
granted -
US 8092830
Lactic acid polymer and process for producing the same
granted -
US 8093382
Dipeptidyl peptidase inhibitors
granted -
US 8093343
Nitric oxide-releasing diazeniumdiolated compounds
granted -
US 8093354
Process for preparing glycopeptide phosphonate derivatives
granted -
US 8092988
Medium and method of deriving and using a mutated bacteria strain
granted -
US 8093246
O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
granted -
US 8093392
Caspase inhibitors and uses thereof
granted -
US 8092812
Methods and compositions for immunization against chlamydial infection and disease
granted -
US 8093280
Methods of preparing imidazole-based compounds
granted -
US 8093236
Weekly administration of dipeptidyl peptidase inhibitors
granted -
US 8093403
Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
granted -
US 8093245
4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use
granted -
US 8092838
Use of hydrogen sulfide in the treatment of eye diseases
granted -
US 8092803
VEGF antagonist formulations for intravitreal administration
granted -
US 8097630
Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
granted -
US 8097612
Compositions and methods relating to novel compounds and targets thereof
granted -
US 8097636
Heterocyclic derivatives as modulators of ion channels
granted -
US 8097695
Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
granted -
US 8097759
Inflammatory cytokine release inhibitor
granted -
US 8097701
Aldehyde tags, uses thereof in site-specific protein modification
granted -
US 8097737
Process for production of optically active amine derivatives
granted -
US 8097713
Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof
granted -
US 8097610
Derivative having PPAR agonistic activity
granted -
US 8097606
Antiglucocorticoids for the treatment of catatonia
granted -
US 8097455
System and method for forming skeletal muscle constructs having functional tissue interfaces
granted -
US 8101637
Alkynyl derivatives as modulators of metatropic glutamate receptors
granted -
US 8101575
Glycopeptide phosphonate derivatives
granted -
US 8101172
Solenopsis invicta virus
granted -
US 8101567
Heteroaryl-containing tripeptide HCV serine protease inhibitors
granted -
US 8101159
In vivo methods of identifying compounds which target suppressed cancer cells
granted -
US 8101174
Pharmaceutical compositions for treating arthritis and inflammatory disease
granted -
US 8101186
Peptides that block the binding of IgG to FcRn
granted -
US 8101198
Osteogenic enhancer composition
granted -
US 8101770
Pyridones useful as inhibitors of kinases
granted -
US 8101745
Lung-targeted drugs
granted -
US 8101724
High-affinity human antibodies to human protease-activated receptor-2
granted -
US 8101643
Benzimidazole derivatives
granted -
US 8101158
Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
granted -
US 8101370
Genes from the 20q13 amplicon and their uses
granted -
US 8101380
Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
granted
Frequently asked questions
How many pharma patents expire in 2032?
1,123 published patents in our USPTO index have expiration dates falling in calendar year 2032.